VJHemOnc is committed to improving our service to you

EBMT 2020 | FLAMSA-reduced intensity vs myeloablative conditioning for R/R AML with disease at transplantation

VJHemOnc is committed to improving our service to you

Eduardo Rodríguez-Arbolí

Eduardo Rodríguez-Arbolí, MD, MPhil, Hospital Universitario Virgen del Rocío, Instituto de Biomedicina de Sevilla (IBIS/CSIC/CIBERONC), University of Seville, Seville, Spain, discusses FLAMSA-based reduced-intensity conditioning versus myeloablative conditioning in patients with relapsed/refractory (R/R) acute myeloid leukemia (AML) with active disease at transplantation. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

Share this video  
Similar topics

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter